中草药

土贝母苷乙通过调控PI3K/Akt通路及LLGL2泛素化抑制结直肠癌细胞增殖和肺转移

PDF下载

中草药 | 药理与临床 2026,57(15): 5931-5941

收起

中草药 |药理与临床 2026 , 57 (15) : 5931 -5941

土贝母苷乙通过调控PI3K/Akt通路及LLGL2泛素化抑制结直肠癌细胞增殖和肺转移

全屏

张甜甜^1,2, 黄家彦¹, 钟昊¹, 杨珅珅², 于海洋³

作者信息

通讯作者:

杨珅珅

作者简介:

张甜甜: 张甜甜，女，硕士，研究方向为中药药理学。E-mail:18019883085@163.com

Tubeimoside II inhibits colorectal cancer cell proliferation and lung metastasis through PI3K/Akt pathway and regulation of LLGL2 ubiquitination

ZHANG Tiantian, HUANG Jiayan, ZHONG Hao, YANG Shenshen, YU Haiyang

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.15.013

文章导航

摘要

收起

目的探究土贝母苷乙（tubeimoside Ⅱ，TUB-Ⅱ）抑制结直肠癌生长和转移的作用机制。方法以人结直肠癌细胞系RKO和SW620为研究对象，检测TUB-Ⅱ对RKO和SW620细胞活力的影响；克隆形成实验检测细胞增殖能力；划痕实验检测细胞迁移能力；Western blotting检测TUB-Ⅱ对RKO和SW620细胞中致死性（2）巨型幼虫同源蛋白2[lethal (2) giant larvae homolog 2，LLGL2]以及上皮-间充质转化（epithelial-mesenchymal transition，EMT）相关蛋白表达的影响；采用免疫共沉淀检测TUB-Ⅱ对LLGL2泛素化的影响。体内构建小鼠皮下瘤模型和结直肠癌肺转移模型，考察TUB-Ⅱ对肿瘤生长和肺转移的影响。结果 TUB-II显著抑制结直肠癌体内外的增殖和转移（P＜0.05、0.01、0.001）。TUB-II显著上调LLGL2的表达（P＜0.05、0.01、0.001），并且抑制磷脂酰肌醇3-激酶（phosphatidylinositol 3-kinase，PI3K）/蛋白激酶B（protein kinase B，Akt）通路的活化（P＜0.05、0.01、0.001），从而抑制肿瘤细胞的增殖和转移。同时TUB-II抑制了双微体同源基因2（murine double minute 2，MDM2）与LLGL2的相互作用来抑制LLGL2的泛素化，从而稳定LLGL2的表达，发挥抗结直肠癌作用。结论 TUB-II抑制结直肠癌的发生发展，其作用机制可能与抑制LLGL2泛素化及PI3K/Akt信号通路相关。

关键词

土贝母苷乙 / 致死性（2）巨型幼虫同源蛋白2 / 双微体同源基因2 / 泛素化 / 结直肠癌

Abstract

收起

Objective To explore the mechanism of tubeimoside II (TUB-II) in inhibiting the growth and metastasis of colorectal cancer. Methods Human colorectal cancer cell lines RKO and SW620 were used as research subjects, the effect of TUB-II on viability of RKO and SW620 cells was detected. The cell proliferation ability was detected by colony formation assay. The cell migration ability was detected by scratch assay. Western blotting was used to detect the effect of TUB-II on expressions of lethal (2) giant larvae homolog 2 (LLGL2) and epithelial-mesenchymal transition (EMT)-related proteins in RKO and SW620 cells. Co-immunoprecipitation was used to detect the effect of TUB-II on ubiquitination of LLGL2. Subcutaneous tumor model and colorectal cancer lung metastasis model in vivo were constructed to investigate the effect of TUB-II on tumor growth and lung metastasis. Results TUB-II significantly inhibited the proliferation and metastasis of colorectal cancer both in vitro and in vivo (P < 0.05, 0.01, 0.001). TUB-II significantly upregulated the expression of LLGL2 (P < 0.05, 0.01, 0.001) and inhibited the activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway (P < 0.05, 0.01, 0.001), thereby suppressing tumor cell proliferation and metastasis. At the same time, TUB-II inhibited the interaction between murine double minute 2 (MDM2) and LLGL2 to suppress the ubiquitination of LLGL2, thereby stabilizing its expression and exerting an anti-colorectal cancer effect. Conclusion TUB-II inhibits the occurrence and development of colorectal cancer, and its mechanism may be related to the inhibition of LLGL2 ubiquitination and PI3K/Akt signaling pathway.

Key words

tubeimoside II / lethal (2) giant larvae homolog 2 / murine double minute 2 / ubiquitination / colorectal cancer

引用本文

张甜甜, 黄家彦, 钟昊, 杨珅珅, 于海洋. 土贝母苷乙通过调控PI3K/Akt通路及LLGL2泛素化抑制结直肠癌细胞增殖和肺转移. 中草药, 2026 , 57 (15) : 5931 -5941 . DOI: 10.7501/j.issn.0253-2670.2026.15.013

ZHANG Tiantian, HUANG Jiayan, ZHONG Hao, YANG Shenshen, YU Haiyang. Tubeimoside II inhibits colorectal cancer cell proliferation and lung metastasis through PI3K/Akt pathway and regulation of LLGL2 ubiquitination[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (15) : 5931 -5941 . DOI: 10.7501/j.issn.0253-2670.2026.15.013

基金

收起

天津市自然科学基金资助项目 (23JCJQJC00040)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Laskar R S, Qu C, Huyghe J R, et al. Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer [J]. Ann Oncol, 2024, 35(6): 523-536.
Underwood P W, Ruff S M, Pawlik T M. Update on targeted therapy and immunotherapy for metastatic colorectal cancer [J]. Cells, 2024, 13(3): 245.
Yue Y Z, Su L L, Wang Y H, et al. Banxia Xiexin Decoction inhibits colitis-associated colorectal cancer development by modulating STAT3 signaling and gut microbiota [J]. Chin Herb Med, 2025, 17(2): 380-391.
Saito Y, Li L, Coyaud E, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER⁺ breast cancer [J]. Nature, 2019, 569(7755): 275-279.
Bii V M, Rudoy D, Klezovitch O, et al. Lethal giant larvae gene family (Llgl1 and Llgl2) functions as a tumor suppressor in mouse skin epidermis [J]. BioRxiv, 2023, doi: 10.1101/2023.03.06.531408.
Hong G L, Kim K H, Kim Y J, et al. Novel role of LLGL2 silencing in autophagy: Reversing epithelial-mesenchymal transition in prostate cancer [J]. Biol Res, 2024, 57(1): 25.
Du D, Xu F L, Yu L H, et al. The tight junction protein, occludin, regulates the directional migration of epithelial cells [J]. Dev Cell, 2010, 18(1): 52-63.
Gu Q Y, Liu Y X, Wang J L, et al. LLGL2 inhibits ovarian cancer metastasis by regulating ctoskeleton remodeling via ACTN1[J]. Cancers, 2023, 15(24): 5880.
Yu T X, Ma R D, Yu L J. Structure-activity relationship of tubeimosides in anti-inflammatory, antitumor, and antitumor-promoting effects [J]. Acta Pharmacol Sin, 2001, 22(5): 463-468.
Wang J Z, Wang C, Jia Y L, et al. Targeted ferroptosis of myofibroblasts by tubeimoside I attenuates hypertrophic scar formation [J]. Front Pharmacol, 2025, 16: 1654108.
Chen Y, Zhu X, Wang K, et al. Tubeimoside II inhibits TGF-β1-induced metastatic progression of human retinoblastoma cells through suppressing redoxosome-dependent EGFR activation [J]. Chem Biol Interact, 2021, 335: 109367.
Zhang Q X, Cheng W J, Li Y, et al. Tubeimoside I inhibits the growth of triple-negative breast cancer via the NR3C2/PI3K/Akt signaling pathway [J]. Naunyn Schmiedeberg’s Arch Pharmacol, 2025, 398(11): 15377-15390.
Wang K, Zhan Y J, Chen B N, et al. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria [J]. Cell Death Dis, 2020, 11: 708.
Liu X J, Yin M X, Dong J W, et al. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR [J]. Acta Pharm Sin B, 2021, 11(10): 3134-3149.
Park A, Joo M, Kim K, et al. A comprehensive evaluation of regression-based drug responsiveness prediction models, using cell viability inhibitory concentrations (IC₅₀ values) [J]. Bioinformatics, 2022, 38(10): 2810-2817.
Leng S S, Xie F, Liu J Y, et al. LLGL2 increases Ca²⁺ influx and exerts oncogenic activities via PI3K/Akt signaling pathway in hepatocellular carcinoma [J]. Front Oncol, 2021, 11: 683629.
Nakayama K I, Nakayama K. Ubiquitin ligases: Cell-cycle control and cancer [J]. Nat Rev Cancer, 2006, 6(5): 369-381.
Koo N, Sharma A K, Narayan S. Therapeutics targeting p53-MDM2 interaction to induce cancer cell death [J]. Int J Mol Sci, 2022, 23(9): 5005.
Wang Z Q, Yue S R, Chen X X, et al. Design of murine double minute 2 proteolysis targeting chimera degraders with a built-in tumor-targeting ability [J]. J Med Chem, 2024, 67(21): 18865-18882.
Wang C, Liu W, Guo H, et al. The intrabody against murine double minute 2 via a p53-dependent pathway induces apoptosis of cancer cell [J]. Int J Mol Sci, 2025, 26(11): 5286.
Huang J Y, Zhang T T, Li H M, et al. Ubiquitination-dependent LLGL2 degradation drives colorectal cancer progression via THBS3 mRNA stabilization [J]. Adv Sci, 2025, 12(39): e01656.
Xu T, Liu Q, Ma H T, et al. Tubeimoside II potentiates anti-PD-1 therapy in NSCLC by increasing ferroptosis sensitivity and remodeling immune landscape [J]. Phytomedicine, 2026, 150: 157660.
Parhira S, Zhu G Y, Wangteeraprasert A, et al. Enhancement of apoptosis in HCT116 and HepG2 cells by Coix lacryma-jobi var. lacryma-jobi seed extract in combination with sorafenib [J]. Chin Herb Med, 2025, 17(2): 322-339.
Roper J, Tammela T, Cetinbas N M, et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis [J]. Nat Biotechnol, 2017, 35(6): 569-576.
Lai Y Y, Xie B, Zhang W T, et al. Pure drug nanomedicines-where we are? [J]. Chin J Nat Med, 2025, 23(4): 385-409.

2026年第57卷第15期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.15.013

接收时间：2026-03-15
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-03-15

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.15.013

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT